Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06310772
Other study ID # NSF 2304297
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 15, 2024
Est. completion date March 1, 2025

Study information

Verified date May 2024
Source Eysz, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study wants to make it easier to find kids with a type of epilepsy called childhood absence epilepsy (CAE) who might have problems with ongoing seizures and thinking. Right now, doctors use tests that can be expensive and take a long time. Eysz is developing a system that looks at how kids move their eyes which might help find CAE more quickly and accurately. This study will compare Eysz with the usual tests to see if it can predict seizures and thinking problems in kids with CAE. The goal is to find these problems earlier and help kids do better in school and life.


Description:

This study addresses the challenges in managing childhood absence epilepsy (CAE), a condition that poses risks of injury and cognitive issues despite normal intelligence levels. Current management relies heavily on subjective reporting and costly, time-consuming tests such as neuropsychiatric assessments and EEGs. However, these methods often underestimate seizure burden and neurocognitive comorbidities, leading to missed opportunities for early intervention. Eysz, a novel system analyzing eye movements, has shown promise in identifying CAE features through passive analysis. Building upon this, the study aims to validate Eysz against established tests like EEGs and questionnaires to develop a rapid and objective tool for identifying CAE in children at risk of poor outcomes due to ongoing seizures or cognitive issues. By evaluating eye-movement features in comparison with hyperventilation, EEG results, and various assessments, the goal is to enable earlier diagnosis, quicker attainment of seizure freedom, and identification of at-risk children who may benefit from interventions to improve cognitive outcomes during critical developmental periods. The study will assess features such as saccade frequency, fixation duration, and eye blink frequency measured by the Eysz system and correlate them with clinical outcomes. By improving the accuracy and efficiency of CAE diagnosis, the study aims to reduce the burden on patients and caregivers while enhancing overall treatment outcomes. Additionally, the findings may contribute to a better understanding of the relationship between eye movements and neurological conditions, potentially opening avenues for future research and intervention strategies. Through collaboration with clinicians and researchers, this study seeks to address the unmet needs in CAE management and ultimately improve the quality of life for affected children and their families.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 1, 2025
Est. primary completion date March 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria: Diagnosis of Childhood Absence Epilepsy by Treating Neurologist or a Healthy control Fluent in English Exclusion Criteria: History of subarachnoid hemorrhage, sickle cell anemia, recent cerebrovascular accident or myocardial infarction, significant cardiopulmonary disease, active asthma, known aneurysm, known moyamoya disease, or pregnancy. Known diagnosis of strabismus or amblyopia Any vision abnormalities that prevent the participant from viewing the screen clearly People who have a history of generalized tonic clonic convulsions To participate as a healthy control the participant must have no personal history of epilepsy, ADHD or other developmental disorder, no first degree relatives with the above diagnosis

Study Design


Locations

Country Name City State
United States Children's Hospital Orange County Orange California
United States Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (4)

Lead Sponsor Collaborator
Eysz, Inc. Children's Hospital of Orange County, University of Colorado, Denver, Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Eye Movements to Diagnose CAE Use machine learning algorithms based on eye movement feature analysis (e.g., saccade frequency and velocity, fixation duration, and eye blink frequency) to identify people with CAE, and those with ongoing seizure activity with > 75% sensitivity and specificity. 1 year
Secondary Eye Movements to Diagnose Attention challenges Use machine learning algorithms based on eye movement feature analysis to identify people with epilepsy whose CPT score indicates attention deficits and those with PESQ score > 34 (1 standard deviation from mean) with > 75% sensitivity and specificity. 1 year
See also
  Status Clinical Trial Phase
Completed NCT00393666 - Why Are Patients With Absence Seizures Absent? A Brain Imaging Study N/A
Terminated NCT06153186 - Flunarizine for Treatment Resistant Absence Epilepsy Phase 2
Enrolling by invitation NCT05109234 - A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Phase 3
Not yet recruiting NCT06315322 - A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Phase 3
Recruiting NCT04666610 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Phase 3
Completed NCT00088452 - Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study Phase 3
Terminated NCT03355300 - Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Phase 2
Terminated NCT03336242 - Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Phase 2
Completed NCT00361010 - A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy N/A
Completed NCT00041951 - Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study N/A